Multiple Myeloma Treatment in Hyderabad
Reviewed June 2026 · Dr. Madhav Danthala
Multiple myeloma is a cancer of plasma cells in the bone marrow. It can cause bone pain, anemia, kidney injury, and infections — but it is one of the most rapidly improving cancers to treat. Care is subtype- and risk-based: modern drug combinations, often followed by autologous stem cell transplant in fit patients, then long-term maintenance to keep the disease in check.
Dr. Madhav Danthala is a hemato-oncologist and BMT physician with 300+ transplants performed and fellowship training at Vancouver General Hospital, Canada. He consults at KIMS-Sunshine Hospitals, Begumpet.
Doctors look for the "CRAB" features — calcium, renal, anemia, bone — to decide when smouldering disease has become myeloma that needs treatment.
When to See a Doctor
Myeloma is often found late because its symptoms — back pain, tiredness, repeated infections — are common and easy to attribute to age or routine wear and tear. The pattern that matters is when these appear together, or when a blood or urine test is unexpectedly abnormal.
Persistent bone or back pain
Bone pain — often in the back or ribs — that persists, worsens at night or rest, or follows a minor injury can reflect myeloma bone lesions rather than ordinary strain.
Unexplained anemia & fatigue
Low haemoglobin with tiredness and breathlessness — especially without an obvious cause like blood loss — can be an early sign when myeloma cells crowd the marrow.
Kidney changes on blood tests
A rising creatinine or unexplained kidney impairment can be the first clue, because the abnormal proteins myeloma produces can injure the kidneys.
Recurrent infections
Because myeloma crowds out healthy antibody-producing cells, repeated chest or other infections can be an early signal, particularly alongside the symptoms above.
Most back pain and fatigue is not myeloma. But when several features cluster — or a protein test is abnormal — a hemato-oncology review is the right step.
Understanding Myeloma
Myeloma exists on a spectrum — from a harmless protein finding, to smouldering disease, to active myeloma that needs treatment.
From MGUS to active myeloma
Many people have a small abnormal protein (MGUS — monoclonal gammopathy of undetermined significance) that never causes harm and only needs monitoring. Smouldering myeloma is an in-between state with more disease but no organ damage. Active myeloma — the kind that needs treatment — is defined by end-organ damage (the CRAB features) or specific high-risk markers. Knowing where a patient sits on this spectrum is the first decision.
How myeloma is diagnosed
Diagnosis uses blood tests (complete blood count, creatinine, calcium), serum protein electrophoresis and free light chains, urine studies, and a bone marrow biopsy with flow cytometry and FISH for genetic risk. Imaging — whole-body low-dose CT, MRI, or PET — assesses bone involvement. See the hemato-oncology page for a video on what a marrow biopsy involves.
First-line treatment & transplant
Most fit patients receive a triplet or quadruplet regimen — a proteasome inhibitor plus an immunomodulatory drug plus dexamethasone, increasingly with a monoclonal antibody (daratumumab). After a good response, an autologous stem cell transplant consolidates remission in eligible patients, followed by maintenance lenalidomide to extend disease control.
Relapsed myeloma
Most myeloma eventually relapses, but there are now many effective next-line options based on prior exposure and response — carfilzomib, pomalidomide, isatuximab, selinexor, and others. For relapsed disease, BCMA-directed CAR-T cell therapy (idecabtagene vicleucel, ciltacabtagene autoleucel) and bispecific antibodies have produced deep remissions. MRD testing may guide depth of response in selected settings.
Supportive & bone care
Protecting bones (bisphosphonates such as zoledronic acid, or denosumab), preventing infection (vaccination, sometimes preventive antibiotics or immunoglobulin), and protecting the kidneys are core parts of care. Pain from bone lesions needs active management, and transfusion support may be needed when counts are low. Good supportive care keeps quality of life high during long-term treatment.
Dr. Danthala's Approach
Myeloma is a marathon, not a sprint — treated in sequential phases over years. Three principles shape the plan.
-
Treat the disease, not just the number
An abnormal protein on its own is not always a reason to treat. MGUS and smouldering myeloma are often monitored. Treatment begins when there is organ damage or high-risk disease — so patients are neither over-treated nor left too late.
-
Aim for a deep, durable remission
Modern combinations and transplant aim for the deepest possible response, then maintenance to hold it. Deeper remissions generally mean longer disease control — which is what extends both years and quality of life.
-
Protect bones, kidneys, and daily life
Because myeloma is lived with over years, supportive care — bone protection, infection prevention, kidney care, pain control — is planned alongside anti-cancer treatment, not as an afterthought.
Treatment Options
Myeloma is treated by combining drug classes that attack plasma cells in different ways, usually followed by transplant in fit patients and long-term maintenance. Below are the major modalities patients should expect to discuss.
Triplet & quadruplet drug combinations
First-line treatment combines a proteasome inhibitor (bortezomib, carfilzomib), an immunomodulatory drug (lenalidomide), and dexamethasone — increasingly with the monoclonal antibody daratumumab. These combinations bring the disease under control before transplant or maintenance.
High-dose therapy with stem-cell rescue
For fit patients, an autologous stem cell transplant — using the patient's own cells, collected and returned after high-dose chemotherapy — deepens and prolongs remission and remains a standard part of first-line treatment. Dr. Danthala has performed 300+ transplants.
Low-intensity therapy to hold remission
After induction and transplant, ongoing maintenance — usually lenalidomide — keeps the disease suppressed for as long as possible. It is generally well tolerated and is one of the main reasons myeloma remissions now last far longer than they once did.
BCMA-directed immunotherapy
For relapsed disease, next-line drug combinations are joined by BCMA-directed CAR-T cell therapy and bispecific antibodies, which have achieved deep remissions in heavily pre-treated patients — a major shift in what relapse can mean.
This is the menu, not the prescription. The right plan depends on genetic risk, fitness, kidney function, and patient preference — built with the patient in the room.
Frequently Asked Questions
Is multiple myeloma curable?
Myeloma is usually controllable for many years rather than routinely cured. Modern combinations have improved survival substantially — many patients now live well for a decade or more. Some achieve long remissions; others need sequential lines of therapy. The goals are deep, durable control, good quality of life, and preventing complications.
When should back pain make me worry about myeloma?
Persistent low back or bone pain that worsens at rest or at night — especially with anemia, fatigue, frequent infections, or kidney changes on blood tests — warrants evaluation. Myeloma can cause bone lesions and fractures. Most back pain is not cancer, but unexplained persistent pain should be checked.
When is a stem cell transplant used for myeloma?
For fit patients, an autologous stem cell transplant after induction therapy deepens and prolongs remission and remains a standard part of first-line treatment. The patient's own stem cells are collected and returned after high-dose chemotherapy. Eligibility depends on age, fitness, and organ function rather than a strict age cut-off.
What is MGUS, and does it always become myeloma?
MGUS (monoclonal gammopathy of undetermined significance) is a common, harmless abnormal protein that only progresses to myeloma in a small fraction of people each year. Most people with MGUS never develop myeloma — it is monitored with periodic blood tests rather than treated. Smouldering myeloma sits between MGUS and active disease and is watched more closely.
How do I book a myeloma consultation in Hyderabad?
Book at KIMS-Sunshine Begumpet via KIMS Hospitals (kimshospitals.com) or KIMS Sunshine (kimssunshine.co.in). Room 545, 5th Floor OPD, Mon–Sat 10 AM–5 PM. Evening clinic at Peoples Polyclinic, Manikonda — call +91 9346524080. A second opinion on the diagnosis and plan is always welcome.
About Dr. Madhav Danthala
Dr. Madhav Danthala is a hemato-oncologist and bone marrow transplant physician at KIMS-Sunshine Hospitals, Begumpet, Hyderabad. He holds a DM in Medical Oncology from NIMS and completed fellowship training in leukemia and bone marrow transplant at Vancouver General Hospital, Canada. He has performed 300+ stem cell transplants and focuses on myeloma, leukemia, lymphoma, transplant, and second opinions.
Trusted guidelines & further reading
- Leukemia & Lymphoma Society — Myeloma Patient information on diagnosis, treatment, and living with myeloma.
- NCI / Cancer.gov — Plasma Cell Neoplasms (including Myeloma) US National Cancer Institute treatment summaries.
- ASCO / Cancer.Net — Multiple Myeloma American Society of Clinical Oncology patient education portal.